{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:22:48Z","timestamp":1789053768641,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.biopha.2018.03.066","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T11:11:25Z","timestamp":1521717085000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer"],"prefix":"10.1016","volume":"102","author":[{"given":"Hilal","family":"Gungor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Eroksuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2018.03.066_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2018.03.066_bib0010","series-title":"Cancer Facts and Figures 2011","year":"2011"},{"key":"10.1016\/j.biopha.2018.03.066_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(05)17706-X","article-title":"Colorectal cancer","volume":"365","author":"Weitz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.03.066_bib0020","doi-asserted-by":"crossref","first-page":"13240","DOI":"10.3390\/ijms131013240","article-title":"The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer","volume":"13","author":"Hersz\u00e9nyi","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2018.03.066_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.03.066_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1472-6890-12-24","article-title":"Lack of MMP-9 expression is a marker for poor prognosis in Dukes\u2019 B colorectal cancer","volume":"12","author":"Koskensalo","year":"2012","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0035","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/bjo.84.6.654","article-title":"Matrix metalloproteinase biology applied to vitreoretinal disorders","volume":"84","author":"Sethi","year":"2000","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.10329","article-title":"Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets","volume":"99","author":"Vihinen","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0045","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/93.3.178","article-title":"Development of matrix metalloproteinase inhibitors in cancer therapy","volume":"93","author":"Hidalgo","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2018.03.066_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10555-007-9105-8","article-title":"The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2","volume":"27","author":"Stetler-Stevenson","year":"2008","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.biopha.2018.03.066_bib0055","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3892\/ijo.2016.3400","article-title":"Insights into the distinct roles of MMP-11 in tumor biology and future therapeutics (review)","volume":"48","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0060","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0065","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.bjc.6600366","article-title":"Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer","volume":"86","author":"Waas","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0070","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.24682","article-title":"Active MMP-2 effectively identifies the presence of colorectal cancer","volume":"125","author":"Murnane","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0075","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ijc.22747","article-title":"Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer","volume":"121","author":"Hilska","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.03.066_bib0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2018.03.066_bib0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2018.03.066_bib0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1734-1140(11)70641-7","article-title":"Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer","volume":"63","author":"Vaish","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2018.03.066_bib0100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/ijc.23315","article-title":"Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells","volume":"122","author":"Xiao","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12029-010-9188-2","article-title":"Chemopreventive effects of non steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study","volume":"42","author":"Vaish","year":"2011","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11010-010-0441-6","article-title":"Alterations in membrane fluidity and dynamics in experimental colon cancer and its chemoprevention by diclofenac","volume":"341","author":"Kaur","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2018.03.066_bib0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mc.20736","article-title":"Diclofenac, a selective COX-2 inhibitor, inhibits DMH-induced colon tumorigenesis through suppression of MCP-1, MIP-1\u03b1 and VEGF","volume":"50","author":"Kaur","year":"2011","journal-title":"Mol. Carcinog."},{"issue":"7","key":"10.1016\/j.biopha.2018.03.066_bib0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/07357907.2017.1337783","article-title":"Role of GSK-3\u03b2 in regulation of canonical Wnt\/\u03b2-catenin signaling and PI3-K\/Akt oncogenic pathway in colon cancer","volume":"35","author":"Jain","year":"2017","journal-title":"Cancer Invest."},{"key":"10.1016\/j.biopha.2018.03.066_bib0125","first-page":"577","article-title":"Evaluation of chemopreventive response of two cycloxygenase-2 inhibitors, etoricoxib and diclofenac in rat colon cancer using FTIR and NMR spectroscopic techniques","volume":"25","author":"Kaur","year":"2010","journal-title":"Nutr. Hosp."},{"key":"10.1016\/j.biopha.2018.03.066_bib0130","first-page":"2895","article-title":"Angiogenesis-, metastasis- and signaling pathway-related factor dynamics in human colon cancer cells following interaction with monocytes","volume":"33","author":"Honda","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2018.03.066_bib0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cam4.20","article-title":"GM-CSF enhances tumor invasion by elevated MMP-2, -9, and -26 expression","volume":"2","author":"Claudia","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2018.03.066_bib0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2005.12.082","article-title":"Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases","volume":"533","author":"Gueders","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0145","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3325\/cmj.2008.5.636","article-title":"Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke\u2019s B colon cancer","volume":"49","author":"Sundov","year":"2008","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.biopha.2018.03.066_bib0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00384-004-0667-4","article-title":"Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer","volume":"20","author":"Langenskiold","year":"2005","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.biopha.2018.03.066_bib0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1025867130437","article-title":"Role of matrix metalloproteinases (MMPs) in colorectal cancer","volume":"23","author":"Zucker","year":"2004","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2018.03.066_bib0160","first-page":"1589","article-title":"MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC)","volume":"26","author":"Guzi\u0144ska-Ustymowicz","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2018.03.066_bib0165","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.humpath.2007.03.018","article-title":"Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer","volume":"38","author":"Cho","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.21601\/ejbms\/9185","article-title":"Matrix metalloproteinases and cancer","volume":"2","author":"Oncel","year":"2012","journal-title":"Eur. J. Basic Med. Sci."},{"key":"10.1016\/j.biopha.2018.03.066_bib0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2003.014472","article-title":"Membrane associated proteases and their inhibitors in tumour angiogenesis","volume":"57","author":"Noel","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s10517-008-0092-8","article-title":"Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer","volume":"145","author":"Gershtein","year":"2008","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.biopha.2018.03.066_bib0185","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.3748\/wjg.v11.i20.3046","article-title":"Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis","volume":"11","author":"Li","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0190","first-page":"1085","article-title":"Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer","volume":"20","author":"Oberg","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2018.03.066_bib0195","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1054\/bjoc.2001.1831","article-title":"Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase","volume":"84","author":"Collins","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0200","first-page":"3387","article-title":"Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples","volume":"25","author":"Pesta","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2018.03.066_bib0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","article-title":"Inflammatory cell infiltration of tumors: Jekyll or Hyde","volume":"26","author":"Talmadge","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2018.03.066_bib0210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.coph.2009.08.003","article-title":"The role of chemokines in intestinal inflammation and cancer","volume":"9","author":"Wang","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12307-010-0052-5","article-title":"Tumor-associated macrophages (TAM) and inflammation in colorectal cancer","volume":"4","author":"Erreni","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.biopha.2018.03.066_bib0220","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/07853890903405753","article-title":"Molecular pathways and targets in cancer-related inflammation","volume":"42","author":"Mantovani","year":"2010","journal-title":"Ann. Med."},{"key":"10.1016\/j.biopha.2018.03.066_bib0225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.03.066_bib0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12307-009-0025-8","article-title":"The tumor microenvironment: the making of a paradigm","volume":"2","author":"Witz","year":"2009","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.biopha.2018.03.066_bib0235","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","article-title":"Wnt signalling in stem cells and cancer","volume":"434","author":"Reya","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2018.03.066_bib0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2015.09.010","article-title":"Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention","volume":"43","author":"Umar","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00428-004-1105-2","article-title":"Cyclooxygenase-2 and its role in colorectal cancer development","volume":"445","author":"Wendum","year":"2004","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2018.03.066_bib0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1185\/03007995.2012.717528","article-title":"Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial","volume":"28","author":"Kellner","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.biopha.2018.03.066_bib0255","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","article-title":"COX-2 as a target for cancer chemotherapy","volume":"62","author":"Ghosh","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2018.03.066_bib0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.03.042","article-title":"The role of COX-2 inhibition in breast cancer treatment and prevention","volume":"31","author":"Arun","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2018.03.066_bib0265","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3816\/CBC.2004.n.006","article-title":"Prognostic impact of Cyclooxygenase-2 in breast cancer","volume":"4","author":"Denkert","year":"2004","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2018.03.066_bib0270","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jsre.2002.6532","article-title":"Role of cyclooxygenase-2 in breast cancer","volume":"108","author":"Singh","year":"2002","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2018.03.066_bib0275","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1541-7786.632.2.11","article-title":"Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer","volume":"2","author":"Basu","year":"2004","journal-title":"Mol. Cancer Res."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217363096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217363096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:01:15Z","timestamp":1731427275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217363096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":55,"alternative-id":["S0753332217363096"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.03.066","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.03.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}